China (Mainland)
Riociguat CAS NO.625115-55-1
- FOB Price: USD: 1.00-1.00 /Kilogram Get Latest Price
- Min.Order: 1 Kilogram
- Payment Terms: T/T,MoneyGram,Other
- Available Specifications:
99%(1-5)Kilogram
- Product Details
Keywords
- 625115-55-1
- C20H19FN8O2
- Methyl (4,6-diaMino-2-(1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl)pyriMidin-5-yl)(Methyl)carbaMate
Quick Details
- ProName: Riociguat
- CasNo: 625115-55-1
- Molecular Formula: C20H19FN8O2
- Appearance: Brownish Orange Solid
- Application: Pharmaceutical Intermediates
- DeliveryTime: customized
- PackAge: carton boxes or fibre drums
- Port: Chinese Main Port
- ProductionCapacity: 100 Kilogram/Month
- Purity: 99%
- Storage: Keep in cool and dry place
- Transportation: by Air or by sea
- LimitNum: 1 Kilogram
- MW: 422.41
- EINECS: 1308068-626-2
Superiority
Career Henan Chemical focus on high complex new type intermediates and fine chemical custom synthesis,scale-up production and rare chemicals. Product category including intermediates&api,catalyst and electronic chemicals.
We have our R&D team and can supply custom made service for chemicals , and keep good relationship with some pharmaceutical companies. Our synthesis level is well-known to the industry, the products are exported to US, France,Poland,Czech,Ukraine,Spain,Switzerland etc.
Career Henan Chemical Co., facing global High-tech pharmaceutical raw materials, high complex new type intermediates, fine chemicals custom synthesis, scale-up production and Rare chemicals trade. Career Chemical have well-equipped machine, strong technical force and considerate marketing team service. We also have rich experience advantage in basic research, small scale process development, scale-up, industrial technology development & production and cost control.
Details
| Riociguat Basic information |
| Product Name: | Riociguat |
| Synonyms: | Riociguat;N-[4,6-Diamino-2-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]-5-pyrimidinyl]-N-methylcarbamic acid methyl ester;Bay 63-2521;Carbamic acid, (4,6-diamino-2-(1-((2-fluorophenyl)methyl)-1H-pyrazolo(3,4-B)pyridin-3-yl)-5-pyrimidinyl)methyl-, methyl ester;Riociguat (BAY 63-2521);Bay63-2521,Riociguat;[4,6-DiaMino-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyriMidin-5-yl]MethylcarbaMic acid Methyl ester;Methyl (4,6-diaMino-2-(1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl)pyriMidin-5-yl)(Methyl)carbaMate |
| CAS: | 625115-55-1 |
| MF: | C20H19FN8O2 |
| MW: | 422.4156632 |
| EINECS: | 1308068-626-2 |
| Product Categories: | API |
| Mol File: | 625115-55-1.mol |
|
|
|
| Riociguat Chemical Properties |
| density | 1.51 |
| Riociguat Usage And Synthesis |
| Pharmacological effects |
Riociguat is a soluble guanylyl cyclase activator, developed by the German Bayer ,it is an important signaling enzyme, which can be activated by nitric oxide (NO) to catalyze guanosine triphosphate ( GTP) to convert into the second messenger cyclic guanosine monophosphate (cGMP). Soluble guanylate cyclase is currently the only known NO receptor. Damage of NO-sGC-cGMP signal pathway is believed to be the cause of the incidence of cardiovascular, lung, endothelium, kidney and liver diseases. NO synthesis in patients with pulmonary hypertension is not enough, NO donor drugs, although effective, short half-life, riociguat can directly activate sGC, stable NO-sGC combination so as to upregulate the second messenger cGMP. riociquat can significantly increase exercise tolerance in patients with hemodynamic parameters of cardiac function and prolong the time to reach clinical worsening (PATENT study), It may also be effective in treating CTEPH(CHEST study) . October 8, 2013, the US FDA approved Riociguat for the treatment of chronic thromboembolic pulmonary hypertension and PAH (Pulmonary Arterial Hypertension). At present, Riociguat is not yet sold in the domestic market ,in the United States it is sold by the Haoeyou Pharmacy , the pharmacy is subsidiary of California Healthcom Group, because the market ofRiociguat is in its infancy, its sales grow slowly. |
| Clinical evaluation |
In clinical trials ,261 patients with chronic thromboembolic pulmonary hypertension (CTEPH) were divided into riociguat and placebo groups, a six-minute walk distance (6MWD) as the main clinical endpoint, after 16 weeks of treatment, 6MWD of riociguat group increased by 46 meters higher than the average in the placebo group. 443 cases of PAH were divided into riociguat and placebo groups,after 12 weeks of treatment, riociguat group increased 36 meters higher than the average 6MWD in the placebo group. Boxed warning suggests that the drug has a embryo toxicity, pregnant patients are forbidden. Adempas is granted baseing on two global III studies CHEST-1 and PATENT-1, whose findings are published in the July 25, 2013"New England Journal of Medicine," (2013; 369: 330-40; 2013; 369: 319-29). Thomson Reuters released analysis report that it is expected that sales of the drug in 2017 will reach $ 679 million, while the market will face a potential threat constituted by the Swiss company Actelion bosentan and Gilead drug Imber bosentan tablets. The above information is edited by the chemicalbook of Tian Ye. |
| Production Method |
Synthetic key of Riociguat is the synthesis of three heterocyclic ring. Compounds 1 and 2 directly close the pyrazole ring to generate 3,3 and 4 and then close the pyrazole ring to obtain5, ethyl of 5 is dehydrated using trifluoroacetic anhydride to give a cyano group after amidation by the ammonia , the cyano group is treated with methanol sodium and chloride ammonium to get amidine 6. The two nitrogen atoms on Amidine 6 as dinucleophile, with two cyano on compound 7 as the electrophile ,directly close the pyrimidine ring to give 8. pyrimidine 5-position amino group on 8 with a strong nucleophilic, directly reacts with methyl chloride and then methylates to give riociguat. Figure 1 is a chemical reactions road map of Riociguat production . |
| Patent cases | US7173037 (there is a deadline to April 25, 2023), US6743798 (valid until July 16, 2019). |
| Chemical Properties | Brownish Orange Solid |
| Uses | Riocguat is used in the treatment for pulmonary hypertension. |
| Definition | ChEBI: A carbamate ester that is the methyl ester of {4,6-diamino-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}methylcarbamic acid. It is used for treatment of chronic thromboembolic pulmonary hypertension an pulmonary arterial hypertension |
